Group
PI3K inhibitor
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | PI3K/AKT/mTOR Pathway Inhibitors |
| Mechanism of Action | PI3K inhibitor |
| Drugs in group | Alpelisib· Inavolisib |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing on the same axis as AKT inhibition (impaired DSB repair, ↓survival signaling), greatest in PI3K-dependent tumors (Petroni et al., Nature Reviews Clinical Oncology, 2022; Barker et al., Nature Reviews Cancer, 2015). Because repair inhibition is not tumor-selective, a theoretical increase in acute in-field mucocutaneous/GI adverse events is plausible, potentially compounded by the class effects of colitis (idelalisib/duvelisib) and pneumonitis.
The data above refer to patients treated with PI3K inhibitor as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.